← All trials
NCT03801668
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 8, 2019
- Primary completion
- Dec 31, 2021
- Completion date
- Mar 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 294
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Huazhong University of Science and TechnologyReponsible party - principal investigator
- Yiling Pharmaceutical Inc.Collaborator
- Huazhong University of Science and TechnologyStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.